{"id":52931,"date":"2026-01-05T23:10:00","date_gmt":"2026-01-05T15:10:00","guid":{"rendered":"https:\/\/flcube.com\/?p=52931"},"modified":"2026-01-05T23:10:01","modified_gmt":"2026-01-05T15:10:01","slug":"frontier-biotechs-fb7013-wins-nmpa-ind-for-masp-2-sirna-in-iga-nephropathy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=52931","title":{"rendered":"Frontier Biotech&#8217;s FB7013 Wins NMPA IND for MASP\u20112 siRNA in IgA Nephropathy"},"content":{"rendered":"\n<p><strong>Frontier Biotechnologies Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688221:SHA\">SHA: 688221<\/a>) announced that it has submitted an <strong>Investigational New Drug (IND)<\/strong> application to the <strong>National Medical Products Administration (NMPA)<\/strong> for <strong>FB7013 Injection<\/strong>, a <strong>self\u2011developed siRNA drug targeting MASP\u20112<\/strong> for the treatment of <strong>primary immunoglobulin A nephropathy (IgA nephropathy)<\/strong>, marking the <strong>world\u2019s first siRNA therapy<\/strong> to address this complement pathway.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-amp-product-milestone\">Regulatory &amp; Product Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>FB7013 Injection<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Frontier Biotechnologies Inc. (688221.SH)<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>IND submitted to NMPA<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Primary IgA nephropathy<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>siRNA targeting MASP\u20112 (lectin pathway)<\/td><\/tr><tr><td><strong>Significance<\/strong><\/td><td><strong>First\u2011in\u2011Class<\/strong> potential; first siRNA targeting MASP\u20112 globally<\/td><\/tr><tr><td><strong>Expansion Potential<\/strong><\/td><td>Membranous nephropathy, diabetic kidney disease<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-mechanism-of-action-amp-differentiation\">Mechanism of Action &amp; Differentiation<\/h2>\n\n\n\n<p><strong>MASP\u20112 Target<\/strong>: FB7013 specifically inhibits <strong>MASP\u20112<\/strong> (mannan\u2011binding lectin serine protease 2), a key protein in the <strong>lectin pathway<\/strong> of the complement system. By blocking abnormal complement activation, FB7013 reduces <strong>complement\u2011mediated kidney tissue damage<\/strong>.<\/p>\n\n\n\n<p><strong>siRNA Advantages<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Long\u2011acting<\/strong>: Potential for <strong>quarterly dosing<\/strong> vs. daily oral therapies<\/li>\n\n\n\n<li><strong>Targeted<\/strong>: Direct knockdown of disease\u2011driving protein in the liver<\/li>\n\n\n\n<li><strong>Safety<\/strong>: Avoids systemic immunosuppression seen with steroids or calcineurin inhibitors<\/li>\n<\/ul>\n\n\n\n<p><strong>Clinical Gap<\/strong>: Current therapies (ACEi\/ARBs, steroids, Nefecon) manage symptoms but <strong>do not address complement\u2011mediated injury<\/strong>; FB7013 offers <strong>disease\u2011modifying potential<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-disease-burden\">Market Opportunity &amp; Disease Burden<\/h2>\n\n\n\n<p><strong>IgA Nephropathy in China<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Prevalence<\/strong>: <strong>~50,000\u201170,000<\/strong> patients with primary IgA nephropathy requiring advanced therapy<\/li>\n\n\n\n<li><strong>Annual Incidence<\/strong>: <strong>5\u20118 per 100,000<\/strong> \u2192 <strong>70,000\u2011110,000<\/strong> new cases annually<\/li>\n\n\n\n<li><strong>Market Size<\/strong>: China IgA nephropathy drug market valued at <strong>\u00a52.5\u202fbillion<\/strong> (2025), growing at <strong>12% CAGR<\/strong><\/li>\n\n\n\n<li><strong>High\u2011Risk Progressors<\/strong>: <strong>30\u201140%<\/strong> develop end\u2011stage kidney disease within <strong>20 years<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Expansion Indications<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Membranous Nephropathy<\/strong>: <strong>~30,000<\/strong> eligible patients<\/li>\n\n\n\n<li><strong>Diabetic Kidney Disease<\/strong>: <strong>3\u20115\u202fmillion<\/strong> patients with complement activation \u2192 <strong>\u00a510\u202fbillion+<\/strong> market potential<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Therapy<\/th><th>Company<\/th><th>Mechanism<\/th><th>Stage (China)<\/th><th>Annual Cost (\u00a5)<\/th><\/tr><\/thead><tbody><tr><td><strong>Nefecon<\/strong><\/td><td>Calliditas\/Pfizer<\/td><td>Targeted release budesonide<\/td><td>Approved (2023)<\/td><td>\u00a580,000\u2011100,000<\/td><\/tr><tr><td><strong>Atrasentan<\/strong><\/td><td>Chinook\/Novartis<\/td><td>Endothelin A antagonist<\/td><td>Phase\u202fIII<\/td><td>Not yet priced<\/td><\/tr><tr><td><strong>Sparsentan<\/strong><\/td><td>Travere<\/td><td>Dual ERA\/ARB<\/td><td>Phase\u202fIII<\/td><td>Not yet priced<\/td><\/tr><tr><td><strong>FB7013<\/strong><\/td><td><strong>Frontier Biotech<\/strong><\/td><td><strong>siRNA targeting MASP\u20112<\/strong><\/td><td><strong>IND submitted<\/strong><\/td><td><strong>\u00a5120,000\u2011150,000<\/strong> (projected)<\/td><\/tr><tr><td><strong>Standard of Care<\/strong><\/td><td>Various<\/td><td>ACEi\/ARBs, steroids<\/td><td>Marketed<\/td><td>\u00a55,000\u201110,000<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>First\u2011Mover Advantage<\/strong>: FB7013 is <strong>24\u201136 months ahead<\/strong> of the next MASP\u20112 targeting therapy (OMS906 from Omeros, Phase\u202fII).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-development-plan\">Clinical Development Plan<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Phase<\/th><th>Design<\/th><th>Primary Endpoints<\/th><th>Timeline<\/th><\/tr><\/thead><tbody><tr><td><strong>Phase\u202fI<\/strong><\/td><td>Dose escalation in IgA nephropathy<\/td><td>Safety, PK, MASP\u20112 knockdown<\/td><td>Initiate Q2\u202f2026<\/td><\/tr><tr><td><strong>Phase\u202fII<\/strong><\/td><td>Efficacy cohort vs. placebo<\/td><td>Proteinuria reduction, eGFR stabilization<\/td><td>2027<\/td><\/tr><tr><td><strong>Phase\u202fIII<\/strong><\/td><td>Registration trial vs. standard of care<\/td><td>Kidney failure prevention<\/td><td>2028\u20112029<\/td><\/tr><tr><td><strong>NDA Filing<\/strong><\/td><td>Rolling submission to NMPA<\/td><td>\u2013<\/td><td>Target <strong>2030<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Orphan Drug Strategy<\/strong>: Eligible for <strong>Orphan Drug Designation<\/strong> in China (prevalence &lt;200,000), providing <strong>7\u2011year market exclusivity<\/strong>.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding FB7013\u2019s clinical development pathway, market opportunity, regulatory strategy, and peak sales potential. Actual results may differ materially due to clinical trial outcomes, competitive dynamics, and regulatory review timelines.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/688221_20260101_UM4H.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688221_20260101_UM4H.\"><\/object><a id=\"wp-block-file--media-b76c2d8c-858e-4f51-b51b-9c60d3bcdc80\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/688221_20260101_UM4H.pdf\">688221_20260101_UM4H<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/688221_20260101_UM4H.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-b76c2d8c-858e-4f51-b51b-9c60d3bcdc80\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Frontier Biotechnologies Inc. (SHA: 688221) announced that it has submitted an Investigational New Drug (IND)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":52936,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[65,90,320,64,1956],"class_list":["post-52931","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-auto-immune","tag-clinical-trial-filings","tag-frontier-biotechnologies","tag-rnai-aso","tag-sha-688221"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Frontier Biotech&#039;s FB7013 Wins NMPA IND for MASP\u20112 siRNA in IgA Nephropathy - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Frontier Biotechnologies Inc. (SHA: 688221) announced that it has submitted an Investigational New Drug (IND) application to the National Medical Products Administration (NMPA) for FB7013 Injection, a self\u2011developed siRNA drug targeting MASP\u20112 for the treatment of primary immunoglobulin A nephropathy (IgA nephropathy), marking the world\u2019s first siRNA therapy to address this complement pathway.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=52931\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Frontier Biotech&#039;s FB7013 Wins NMPA IND for MASP\u20112 siRNA in IgA Nephropathy\" \/>\n<meta property=\"og:description\" content=\"Frontier Biotechnologies Inc. (SHA: 688221) announced that it has submitted an Investigational New Drug (IND) application to the National Medical Products Administration (NMPA) for FB7013 Injection, a self\u2011developed siRNA drug targeting MASP\u20112 for the treatment of primary immunoglobulin A nephropathy (IgA nephropathy), marking the world\u2019s first siRNA therapy to address this complement pathway.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=52931\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-05T15:10:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-05T15:10:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0509.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52931#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52931\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Frontier Biotech&#8217;s FB7013 Wins NMPA IND for MASP\u20112 siRNA in IgA Nephropathy\",\"datePublished\":\"2026-01-05T15:10:00+00:00\",\"dateModified\":\"2026-01-05T15:10:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52931\"},\"wordCount\":454,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52931#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0509.webp\",\"keywords\":[\"Auto-immune\",\"Clinical trial filings\",\"Frontier Biotechnologies\",\"RNAi \\\/ ASO\",\"SHA: 688221\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52931#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52931\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=52931\",\"name\":\"Frontier Biotech's FB7013 Wins NMPA IND for MASP\u20112 siRNA in IgA Nephropathy - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52931#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52931#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0509.webp\",\"datePublished\":\"2026-01-05T15:10:00+00:00\",\"dateModified\":\"2026-01-05T15:10:01+00:00\",\"description\":\"Frontier Biotechnologies Inc. (SHA: 688221) announced that it has submitted an Investigational New Drug (IND) application to the National Medical Products Administration (NMPA) for FB7013 Injection, a self\u2011developed siRNA drug targeting MASP\u20112 for the treatment of primary immunoglobulin A nephropathy (IgA nephropathy), marking the world\u2019s first siRNA therapy to address this complement pathway.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52931#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52931\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52931#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0509.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0509.webp\",\"width\":1080,\"height\":608,\"caption\":\"Frontier Biotech's FB7013 Wins NMPA IND for MASP\u20112 siRNA in IgA Nephropathy\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52931#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Frontier Biotech&#8217;s FB7013 Wins NMPA IND for MASP\u20112 siRNA in IgA Nephropathy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Frontier Biotech's FB7013 Wins NMPA IND for MASP\u20112 siRNA in IgA Nephropathy - Insight, China&#039;s Pharmaceutical Industry","description":"Frontier Biotechnologies Inc. (SHA: 688221) announced that it has submitted an Investigational New Drug (IND) application to the National Medical Products Administration (NMPA) for FB7013 Injection, a self\u2011developed siRNA drug targeting MASP\u20112 for the treatment of primary immunoglobulin A nephropathy (IgA nephropathy), marking the world\u2019s first siRNA therapy to address this complement pathway.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=52931","og_locale":"en_US","og_type":"article","og_title":"Frontier Biotech's FB7013 Wins NMPA IND for MASP\u20112 siRNA in IgA Nephropathy","og_description":"Frontier Biotechnologies Inc. (SHA: 688221) announced that it has submitted an Investigational New Drug (IND) application to the National Medical Products Administration (NMPA) for FB7013 Injection, a self\u2011developed siRNA drug targeting MASP\u20112 for the treatment of primary immunoglobulin A nephropathy (IgA nephropathy), marking the world\u2019s first siRNA therapy to address this complement pathway.","og_url":"https:\/\/flcube.com\/?p=52931","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-05T15:10:00+00:00","article_modified_time":"2026-01-05T15:10:01+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0509.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=52931#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=52931"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Frontier Biotech&#8217;s FB7013 Wins NMPA IND for MASP\u20112 siRNA in IgA Nephropathy","datePublished":"2026-01-05T15:10:00+00:00","dateModified":"2026-01-05T15:10:01+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=52931"},"wordCount":454,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=52931#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0509.webp","keywords":["Auto-immune","Clinical trial filings","Frontier Biotechnologies","RNAi \/ ASO","SHA: 688221"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=52931#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=52931","url":"https:\/\/flcube.com\/?p=52931","name":"Frontier Biotech's FB7013 Wins NMPA IND for MASP\u20112 siRNA in IgA Nephropathy - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=52931#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=52931#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0509.webp","datePublished":"2026-01-05T15:10:00+00:00","dateModified":"2026-01-05T15:10:01+00:00","description":"Frontier Biotechnologies Inc. (SHA: 688221) announced that it has submitted an Investigational New Drug (IND) application to the National Medical Products Administration (NMPA) for FB7013 Injection, a self\u2011developed siRNA drug targeting MASP\u20112 for the treatment of primary immunoglobulin A nephropathy (IgA nephropathy), marking the world\u2019s first siRNA therapy to address this complement pathway.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=52931#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=52931"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=52931#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0509.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0509.webp","width":1080,"height":608,"caption":"Frontier Biotech's FB7013 Wins NMPA IND for MASP\u20112 siRNA in IgA Nephropathy"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=52931#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Frontier Biotech&#8217;s FB7013 Wins NMPA IND for MASP\u20112 siRNA in IgA Nephropathy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0509.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52931","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=52931"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52931\/revisions"}],"predecessor-version":[{"id":52937,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52931\/revisions\/52937"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/52936"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=52931"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=52931"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=52931"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}